Report Id: SNS/HC/1515 | May 2022 | Region: Global | 125 Pages
Report Scope & Overview:
Uveitis Treatment Market Size was valued at USD 616.7 million in 2022 and is expected to reach USD 975.6 million by 2030, and grow at a CAGR of 5.9% over the forecast period 2023-2030.
Uveitis is an inflammation of the iris, choroid, and ciliary body, which make up the middle layer of tissue in the uvea of the eyewall. Uveitis is treated with a variety of medications, including cycloplegic agents, anti-inflammatory, antibacterial treatments, immunotherapy, targeted therapies, and others. Anterior uveitis, middle uveitis, posterior uveitis, and panuveitis are all kinds of uveitis. The most continuous sort of uveitis is iritis, or foremost uveitis, which is an irritation of the iris.
The uveitis treatment market is predicted to develop due to an increase in the prevalence of uveitis and more awareness among patients, as well as increased usage of sophisticated therapies. The unknown aetiology and pathophysiology of uveitis, on the other hand, is expected to stymie market expansion. Furthermore, developing nations' untapped potential presents significant chances for market expansion during the projection period.
R&D spending in the healthcare industry has increased.
Uveitis is becoming more common over the world.
Corticosteroid drug-related side effects
The presence of state-of-the-art medical facilities
High cost of treatment
IMPACT OF COVID-19
The COVID-19 pandemic had an influence on the market in the form of disturbed care patterns, which could lead to changes in illness management across a variety of treatment domains. Ophthalmology was one of the most afflicted disciplines in medicine during the early period, with significant restrictions on some surgeries and permission to perform only the most necessary procedures. As per research, uveitis patients are more probable than everybody to get COVID-19, bringing about a more extreme Covid contamination. Because of these elements, the interest for uveitis treatment meds is supposed to stay stable across different geologies.
By Drug Class
Anti-inflammatory, antibacterial medications, immunotherapy & targeted treatments, and others make up the uveitis treatment industry. Anti-inflammatory drugs are currently a key revenue contributor, and they are expected to rise significantly over the projected period as anti-inflammatory drugs become the first-line treatment for uveitis. Eye drops, pills, and injections are all options for anti-inflammatory drugs. Anti-inflammatory eye drops may not penetrate well enough to reach the rear of the eye, hence they are not recommended for posterior uveitis. If topical corticosteroids haven't worked for intermediate or posterior uveitis, corticosteroid injections or shots are used to relieve inflammation. The immunotherapy and targeted treatments category, on the other hand, is predicted to develop at the highest rate due to increased demand for appropriate medications for the treatment of uveitis. In the therapy of uveitis, immunosuppressive medications such as azathioprine, cyclosporine, methotrexate, mycophenolate, and others are available.
By Disease Type
Anterior uveitis, posterior uveitis, intermediate uveitis, and panuveitis are the four types of uveitis on the market. Because of the greater prevalence of uveitis, the anterior uveitis sector is expected to grow significantly during the projected period. The most common type of uveitis is anterior uveitis, which is marked by inflammation of the main layer of the eye, which includes the iris and neighboring tissue known as the ciliary body.
Some of the major key players are as: Allergan PLC, Alimera Sciences, Bausch Health, EyePoint Pharmaceuticals, Inc., AbbVie Inc., Horizon Therapeutics Plc, Mylan NV, Novartis AG, and other players.
By Drug Type
Immunotherapy & Targeted Therapies
By Disease Type
By Distribution Channel type
Drug Stores & Retail Pharmacies
The increased prevalence of noninfectious uveitis in the United States helped North America lead the market. Furthermore, excellent healthcare facilities and advantageous reimbursement regulations are credited with boosting regional development. The United States has a significant number of commercially available medications, which is increasing demand.
Growing R&D initiatives, as well as increased healthcare expenditures in Europe, resulted in significant revenue. A crucial aspect driving regional growth is the increasing number of elderly people.
In contrast, Asia Pacific is expected to grow at a healthy rate during the projected period, owing to the increased frequency of infectious diseases and a lack of cleanliness in the developing world. Growing awareness of the numerous treatment options has also resulted in rapid regional expansion.
Rest of Europe
Rest of Asia-Pacific
The Middle East & Africa
Rest of Middle East & Africa
Rest of Latin America
|Market Size in 2022||US$ 582.4 Million|
|Market Size by 2030||US$ 870.02 Million|
|CAGR||CAGR of 5.9% From 2023 to 2030|
|Report Scope & Coverage||Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook|
|Key Segments||• By Drug type (Anti-inflammatory, Immunotherapy & Targeted Therapies, Antimicrobial Drugs, Others)
• By Disease Type (Anterior Uveitis, Intermediate Uveitis, Posterior Uveitis, Panuveitis)
• By Distribution Channel type (Hospital Pharmacies, Online pharmacies, rug Stores & Retail Pharmacies)
|Regional Analysis/Coverage||North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
|Company Profiles||Allergan PLC, Alimera Sciences, Bausch Health, EyePoint Pharmaceuticals, Inc., AbbVie Inc., Horizon Therapeutics Plc, Mylan NV, Novartis AG, and other players.|
|DRIVERS||• R&D spending in the healthcare industry has increased.
• Uveitis is becoming more common over the world.
|RESTRAINTS||• Corticosteroid drug-related side effects|
Frequently Asked Questions (FAQ) :
Corticosteroid drug-related side effects are the main restraints of the Uveitis Treatment market.
R&D spending in the healthcare industry has increased, Uveitis is becoming more common over the world are all propelling Uveitis Treatment market forward.
The increased prevalence of noninfectious uveitis in the United States helped North America lead the market.
Allergan PLC, Alimera Sciences, Bausch Health, EyePoint Pharmaceuticals, Inc., and AbbVie Inc. are the key players in the Uveitis Treatment Market.
Uveitis Treatment Market Size was valued at USD 582.4 million in 2021.
Table of Contents
1.1 Market Definition
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
4.1 COVID-19 Impact Analysis
4.2 Impact of Ukraine- Russia war
4.3 Impact of ongoing Recession
4.3.2 Impact on major economies
220.127.116.11 United Kingdom
18.104.22.168 South Korea
22.214.171.124 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Uveitis Treatment Market Segmentation, By Drug type
8.2 Immunotherapy & Targeted Therapies
8.3 Antimicrobial Drugs
9. Uveitis Treatment Market Segmentation, By Disease Type
9.1 Anterior Uveitis
9.2 Intermediate Uveitis
9.3 Posterior Uveitis
10. Uveitis Treatment Market Segmentation, By Distribution Channel type
102 Online pharmacies
10.3Drug Stores & Retail Pharmacies
11. Regional Analysis
11.2 North America
11.3.6 The Netherlands
11.3.7 Rest of Europe
11.4.2 South Korea
11.4.6 Rest of Asia-Pacific
11.5 The Middle East & Africa
11.5.3 South Africa
11.6 Latin America
11.6.3 Rest of Latin America
12. Company Profiles
12.1 Allergan PLC
12.1.2 Products/ Services Offered
12.1.3 SWOT Analysis
12.1.4 The SNS view
12.2 Alimera Sciences
12.3 Bausch Health
12.4EyePoint Pharmaceuticals, Inc.
12.5 AbbVie Inc.
12.6 Horizon Therapeutics Plc
12.7 Mylan NV
12.8 Novartis AG.
13. Competitive Landscape
13.1 Competitive Benchmark
13.2 Market Share Analysis
13.3 Recent Developments
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.